olmesartan has been researched along with Cognitive Decline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hasegawa, Y; Kim-Mitsuyama, S; Matsui, K; Nakagata, N; Nakagawa, T; Senju, S; Uekawa, K | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Nakagawa, T; Uekawa, K | 1 |
2 other study(ies) available for olmesartan and Cognitive Decline
| Article | Year |
|---|---|
Transient Mild Cerebral Ischemia Significantly Deteriorated Cognitive Impairment in a Mouse Model of Alzheimer's Disease via Angiotensin AT1 Receptor.
Topics: Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebrovascular Circulation; Cognitive Dysfunction; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Ischemic Attack, Transient; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Receptor, Angiotensin, Type 1; Tetrazoles | 2017 |
Chronic kidney disease accelerates cognitive impairment in a mouse model of Alzheimer's disease, through angiotensin II.
Topics: Aging; Alzheimer Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Blood-Brain Barrier; Cognition; Cognitive Dysfunction; Disease Models, Animal; Hippocampus; Imidazoles; Maze Learning; Memory; Mice; Mice, Transgenic; Oxidative Stress; Renal Insufficiency, Chronic; Tetrazoles | 2017 |